Sinopharm

Sinopharm experienced steady revenue growth up to 2023; however, 2024 marked a significant downturn. The year proved challenging, with notable revenue and operating profit declines, reflecting wider pressures within the healthcare sector. The revenue drop in 2024 was driven by several factors, including stagnation in the pharmaceutical distribution market, difficulties in working capital management, and reduced medical device distribution segment turnover. Additionally, the company was impacted by broader market dynamics and ongoing service transformation within the healthcare industry. In the first half of 2025, there was a slight decrease in total assets by 0.37% and a modest increase in net assets attributable to shareholders by 2.02%. Revenue grew by 3.54% compared to the same period last year, while total profit and net profit attributable to shareholders declined by 6.92% and 5.19% respectively. The company also reported a negative net cash flow from operating activities, indicating potential cash management challenges. These financial indicators suggest a mixed performance, with revenue growth but a decline in profitability, which may impact the company’s market positioning and stakeholder confidence.

Sinopharm Group Co. Ltd. was founded in Shanghai in January 2003 and listed on the Hong Kong Stock Exchange (01099.HK) in September 2009. The group now comprises over 1,100 subsidiaries, including two A-share listed companies: Sinopharm (CNCM LTD) and Sinopharm Accord.

Since its inception, under the guidance of CNPGC, Sinopharm has aligned closely with national policies and industry trends, driving the transformation and integration of China’s pharmaceutical distribution sector and emerging as a market leader. The company has established a fully integrated supply chain ecosystem centered on pharmaceutical and medical device distribution, while also extending into pharmaceutical manufacturing, medical devices, chemical reagents, and related fields. Today, Sinopharm is a leading distributor and retailer of pharmaceuticals, medical devices, and healthcare products, as well as a top supply-chain service provider in China.

In 2024, Sinopharm achieved revenue of RMB 584.5 billion. Its pharmaceutical distribution business strengthened its leadership, serving over 700,000 customers across provinces, autonomous regions, and municipalities, while steadily expanding market share. The medical device business demonstrated strong network coverage, enhanced comprehensive service capabilities, and promoted industrial manufacturing. The retail network continued to optimize operations, now encompassing over 10,000 pharmacies, with traditional and speciality outlets maintaining steady growth. Sino Biopharmaceutical Limited reported strong financial results for the first half of 2025, with revenue reaching RMB 17.57 billion, representing a 10.7% increase year-on-year. The Chinese pharmaceutical conglomerate's profit attributable to owners from continuing operations surged 140.2% to RMB3.39 billion, driven by strong revenue growth and increased investment returns.

Guided strategically by CNPGC, Sinopharm remains committed to its role as a centrally-administered pharmaceutical enterprise, advancing the “Healthy China” strategy, safeguarding public health, and meeting the growing demand for quality healthcare services.